O'Reilly Linda P, Luke Cliff J, Perlmutter David H, Silverman Gary A, Pak Stephen C
Department of Pediatrics, Cell Biology and Physiology, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh of UPMC, 4401 Penn Avenue, Pittsburgh, PA 15224,USA.
Department of Pediatrics, Cell Biology and Physiology, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh of UPMC, 4401 Penn Avenue, Pittsburgh, PA 15224,USA.
Adv Drug Deliv Rev. 2014 Apr;69-70:247-53. doi: 10.1016/j.addr.2013.12.001. Epub 2013 Dec 12.
Caenorhabditis elegans has been proven to be a useful model organism for investigating molecular and cellular aspects of numerous human diseases. More recently, investigators have explored the use of this organism as a tool for drug discovery. Although earlier drug screens were labor-intensive and low in throughput, recent advances in high-throughput liquid workflows, imaging platforms and data analysis software have made C. elegans a viable option for automated high-throughput drug screens. This review will outline the evolution of C. elegans-based drug screening, discuss the inherent challenges of using C. elegans, and highlight recent technological advances that have paved the way for future drug screens.
秀丽隐杆线虫已被证明是研究多种人类疾病分子和细胞层面的有用模式生物。最近,研究人员探索了将这种生物用作药物发现工具。尽管早期的药物筛选劳动强度大且通量低,但高通量液体工作流程、成像平台和数据分析软件的最新进展使秀丽隐杆线虫成为自动高通量药物筛选的可行选择。本综述将概述基于秀丽隐杆线虫的药物筛选的发展历程,讨论使用秀丽隐杆线虫的内在挑战,并突出为未来药物筛选铺平道路的最新技术进展。